Fresh analysis suggests that people who discontinue popular GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end conventional lifestyle programs.
Findings released in a major medical journal shows that while overweight individuals can lose a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing such treatments should be aware of the risk of rapid weight regain when the treatment ends," stated expert Dr. Susan Jebb.
That rate of recovery suggests a reversion to original weight within about 18 months.
Weighing Treatments
The analysis, which examined dozens of studies involving thousands of patients, contrasted the effects of GLP-1 agonists with other pills.
Scientists point out that individuals who shed pounds through dieting generally experience a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Fast Regain
Nutrition scientists suggest the mechanism of the jabs explains the accelerated weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' means hunger is no longer kept in check, making binge eating a significant risk."
An Ongoing Condition?
Medical guidelines advise the jabs for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, considering the likelihood of relapse, the treatment is often life-long.
This view is supported by pharmaceutical companies, who state that the results "emphasize the chronic character of excess weight," comparing it to managing conditions like diabetes.
Patient Testimonies
Individuals who have come off the jabs report a powerful resurgence of appetite.
"I experienced a switch that goes on and I was suddenly extremely hungry," recalled an individual.
This difficulty is worsened if users have not established sustainable lifestyle or habit modifications during treatment.
Growing Use
Survey data suggest that millions of people in the UK have used these injections in the last 12 months, with desire continuing to grow.
- Adoption is more common among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, clinicians stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone solution and lasting health benefits likely depends on ongoing behavioural management.
